417 related articles for article (PubMed ID: 23462785)
1. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785
[TBL] [Abstract][Full Text] [Related]
2. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
Baddley JW; Winthrop KL; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
Ann Rheum Dis; 2014 Nov; 73(11):1942-8. PubMed ID: 23852763
[TBL] [Abstract][Full Text] [Related]
3. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
Grijalva CG; Chen L; Delzell E; Baddley JW; Beukelman T; Winthrop KL; Griffin MR; Herrinton LJ; Liu L; Ouellet-Hellstrom R; Patkar NM; Solomon DH; Lewis JD; Xie F; Saag KG; Curtis JR
JAMA; 2011 Dec; 306(21):2331-9. PubMed ID: 22056398
[TBL] [Abstract][Full Text] [Related]
4. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
5. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
6. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
[TBL] [Abstract][Full Text] [Related]
7. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
[TBL] [Abstract][Full Text] [Related]
9. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
10. Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases.
Kawai VK; Grijalva CG; Arbogast PG; Curtis JR; Solomon DH; Delzell E; Chen L; Ouellet-Hellstrom R; Herrinton L; Liu L; Mitchell EF; Stein CM; Griffin MR
Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1085-94. PubMed ID: 23281339
[TBL] [Abstract][Full Text] [Related]
11. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.
Winthrop KL; Chen L; Fraunfelder FW; Ku JH; Varley CD; Suhler E; Hills WL; Gattey D; Baddley JW; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Herrinton LJ; Fraunfelder FT; Saag KG; Lewis JD; Solomon DH; Curtis JR
Am J Ophthalmol; 2013 Jan; 155(1):183-189.e1. PubMed ID: 22967869
[TBL] [Abstract][Full Text] [Related]
12. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.
Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
Arthritis Rheum; 2007 Dec; 57(8):1431-8. PubMed ID: 18050184
[TBL] [Abstract][Full Text] [Related]
13. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
15. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.
Zhang J; Xie F; Delzell E; Chen L; Winthrop KL; Lewis JD; Saag KG; Baddley JW; Curtis JR
JAMA; 2012 Jul; 308(1):43-9. PubMed ID: 22760290
[TBL] [Abstract][Full Text] [Related]
16. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
Arthritis Care Res (Hoboken); 2015 May; 67(5):731-6. PubMed ID: 25201241
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic arthritis treatment and the risk of herpes zoster.
Zisman D; Bitterman H; Shalom G; Feldhamer I; Comanesther D; Batat E; Greenberg-Dotan S; Cohen S; Cohen AD
Ann Rheum Dis; 2016 Jan; 75(1):131-5. PubMed ID: 25261573
[TBL] [Abstract][Full Text] [Related]
18. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
19. The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service - Sample cohort database.
Lim DH; Kim YJ; Kim SO; Hong S; Lee CK; Yoo B; Kim YG
Mod Rheumatol; 2018 Jan; 28(1):168-173. PubMed ID: 28548546
[TBL] [Abstract][Full Text] [Related]
20. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
